EMJ Cardiology 10 [Supplement 5] . 2022

In this issue

Highlighting a presentation that took place as part of the European Society of Cardiology’s (ESC) Heart Failure 2022 congress, this article summarised data on the efficacy and safety of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Ahmad Masri, Medical Doctor and Director of the Hypertrophic Cardiomyopathy Centre at Oregon Health & Science University, Portland, USA, spoke about the ongoing REDWOOD-HCM open-label extension (OLE) trial, a continuation of the Phase II REDWOOD-HCM trial. He began by describing the study design of REDWOOD-HCM OLE, including the screening and enrolment processes. Additionally, Masri discussed the baseline characteristics of the patients enrolled in the study.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?